#Israel #Inspira Technologies #INSPIRA ART100 #Ra'anana #respiratory devices

Inspira Technologies Prepares for Increased Production

In the wake of a recent outbreak of human metapneumovirus (hMPV) in China, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is set to increase production of its flagship respiratory support device, the INSPIRA™ ART100. This proactive measure underscores the company’s commitment to addressing urgent healthcare needs amid rising infectious diseases.

Strategic Response to Health Crisis

Inspira has been closely monitoring global health trends and engaging with healthcare providers in regions affected by the hMPV outbreak. The company's leadership recognizes the crucial role that advanced respiratory care technologies like the INSPIRA™ ART100 can play in saving lives during respiratory health crises. Dagi Ben-Noon, CEO of Inspira, stated, “While hMPV is not an entirely new virus, our objective is to be prepared to meet any surge in demand for respiratory support.”

This willingness to respond is timely, as health authorities around the world are keeping a close eye on emerging viral threats. With an ever-increasing number of patients needing respiratory assistance, Inspira believes that its innovative solutions can help alleviate the strain on healthcare systems.

Innovations in Respiratory Care

The INSPIRA™ ART100 leverages cutting-edge technology designed to improve patient outcomes without the invasive procedures often associated with traditional mechanical ventilators. By elevating and stabilizing oxygen saturation levels quickly, it supports patients in remaining awake and engaged during treatment. This is especially vital for intensive care patients who are increasingly reliant on effective respiratory interventions.

Moreover, the system is equipped with the HYLA™ blood sensor, enabling continuous monitoring of a patient’s condition. This real-time data provision allows healthcare professionals to make timely, informed decisions without the interruptions of routine blood sampling, while potentially enhancing patient comfort and care efficiency.

With FDA 510(k) clearance for essential medical applications and relevant certifications acquired in Israel, Inspira is solidifying its position as a key player in the respiratory device market. Its forward-thinking products are part of a larger strategy to provide innovative solutions within the burgeoning $19 billion mechanical ventilation sector, responding to approximately 20 million patients annually who suffer from acute respiratory failures worldwide.

Commitment to Global Health

Inspira’s readiness extends beyond just production capabilities. Collaborating deeply with suppliers, the company is ensuring an uninterrupted supply chain for the components necessary to meet anticipated demand. “Our measures are precautionary but crucial,” Ben-Noon emphasized, reflecting Inspira’s dedication to global health preparation.

As the situation progresses, Inspira Technologies will continue to adapt its production plans according to health authority guidelines and the evolving circumstances surrounding hMPV. This reinforces the company's integral role in safeguarding public health through innovation and readiness.

As Inspira prepares for the potential surge in demand, its focus remains steadfast: providing healthcare professionals around the globe with the vital tools needed to deliver life-saving care. The commitment to quality, innovation, and rapid responsiveness positions Inspira as a leader in the fight against respiratory illnesses, ready to meet the challenges of an unpredictable health landscape.

For more information on Inspira Technologies, visit their official website.